Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — December 2020

Planlagt Fastgjort Låst Flyttet Genmab
1.1k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • D Offline
    D Offline
    Doublo
    wrote on sidst redigeret af
    #144

    Zackb det mangler jeg også, en af de mest irriterende fejl på Google er, at gamle opslag ikke slettes, så der kommer et utal af gamle kursmål op når man søger. Jeg har dog både set 2700 og 3000 som kursmål.

    1 Reply Last reply
    0
    • BulderB Offline
      BulderB Offline
      Bulder
      wrote on sidst redigeret af
      #145

      Jeg har lagt et excel-ark op i debatten med de kursmål, jeg ligger inde med.

      1 Reply Last reply
      0
      • P Offline
        P Offline
        peter12
        wrote on sidst redigeret af
        #146

        Lidt mere om vores ven https://www.tmc.edu/news/2020/01/meet-2019-stat-wunderkind-limo-chen-ph-d-of-md-anderson-cancer-center/

        1 Reply Last reply
        0
        • BulderB Offline
          BulderB Offline
          Bulder
          wrote on sidst redigeret af
          #147

          Ja, her gentager han det med PD-(L)1 og CD38. Spørgsmålet er om han har arbejdet videre med det.

          1 Reply Last reply
          0
          • BulderB Offline
            BulderB Offline
            Bulder
            wrote on sidst redigeret af
            #148

            Sanofi kører et studie i Isatuximab + Cemiplimab mod bl.a. NSCLC. Winkel har tidligere sagt, at de vil afvente resultater fra dette studie, før der tages stilling til en evt. genoptagelse af daratumumab i solide.
            https://www.clinicaltrials.gov/ct2/show/NCT03367819?term=isatuximab+solid+tumor&draw=2&rank=1

            1 Reply Last reply
            0
            • P Offline
              P Offline
              peter12
              wrote on sidst redigeret af
              #149

              Jeg ved ikke om dette har været linket før https://clincancerres.aacrjournals.org/content/26/9/2203

              1 Reply Last reply
              0
              • BulderB Offline
                BulderB Offline
                Bulder
                wrote on sidst redigeret af
                #150

                Det interessante ved sanofi's studie er, at det kører uden dexamethason (ser det ud til), som Winkel i sin tid udpegede som den mulige skurk i fadæsen.

                1 Reply Last reply
                0
                • BulderB Offline
                  BulderB Offline
                  Bulder
                  wrote on sidst redigeret af
                  #151

                  JNJ-7957 er det samme som teclistamab. peter's link er det prækliniske studie, som har ført videre til klinisk studie i dara+teclistamab i MM https://www.clinicaltrials.gov/ct2/show/NCT04108195?term=daratumumab+teclistamab&draw=2&rank=1

                  1 Reply Last reply
                  0
                  • BulderB Offline
                    BulderB Offline
                    Bulder
                    wrote on sidst redigeret af
                    #152

                    Hvis Genmab/Janssen beslutter sig for at prøve igen med CD38 som mål for angreb på solide, bliver det nok ikke med dara men Hexabody cd38.

                    1 Reply Last reply
                    0
                    • G Offline
                      G Offline
                      GeorgeBest
                      wrote on sidst redigeret af
                      #153

                      Var det leukemi udover MM som de ville afprøve hexa-cd38 imod?

                      1 Reply Last reply
                      0
                      • BulderB Offline
                        BulderB Offline
                        Bulder
                        wrote on sidst redigeret af
                        #154

                        Fra aftalen med Janssen: HexaBody-CD38 could be superior to daratumumab for certain tumor cell types and may expand and extend the promise of CD38-targeted therapies for more patients with multiple myeloma, lymphoma, leukemia, and potentially beyond.

                        1 Reply Last reply
                        0
                        • BulderB Offline
                          BulderB Offline
                          Bulder
                          wrote on sidst redigeret af
                          #155

                          https://ir.genmab.com/news-releases/news-release-details/genmab-signs-agreement-janssen-next-generation-cd38-antibody/

                          1 Reply Last reply
                          0
                          • BulderB Offline
                            BulderB Offline
                            Bulder
                            wrote on sidst redigeret af
                            #156

                            "beyond" kunne jo være solide?

                            1 Reply Last reply
                            0
                            • G Offline
                              G Offline
                              GeorgeBest
                              wrote on sidst redigeret af
                              #157

                              Ja klart

                              1 Reply Last reply
                              0
                              • SolsenS Offline
                                SolsenS Offline
                                Solsen
                                wrote on sidst redigeret af
                                #158

                                Hexa38 har præklinisk vist rigtig god effekt i DLBCL. Epco er også god her, men ellers en meget svær sygdom at kæmpe imod.

                                1 Reply Last reply
                                0
                                • E Offline
                                  E Offline
                                  E_L
                                  wrote on sidst redigeret af
                                  #159

                                  https://twitter.com/HenrychihangFu1/status/1335039190845845504

                                  1 Reply Last reply
                                  0
                                  • E Offline
                                    E Offline
                                    E_L
                                    wrote on sidst redigeret af
                                    #160

                                    Dr Mark Wildgust: Updated APOLLO Trial Results Confirm Daratumumab Safety in Multiple Myeloma https://www.ajmc.com/view/dr-mark-wildgust-updated-apollo-trial-results-confirm-daratumumab-safety-in-multiple-myeloma - ONLY
                                    5% of patients had infusion-related reactions in the APOLLO study, and all of those were grade 1/grade 2. So real confirmation that subcu dara is well tolerated.

                                    1 Reply Last reply
                                    0
                                    • E Offline
                                      E Offline
                                      E_L
                                      wrote on sidst redigeret af
                                      #161

                                      https://genmab-at-ash-2020.com/ genmab-at-ash-2020

                                      1 Reply Last reply
                                      0
                                      • E Offline
                                        E Offline
                                        E_L
                                        wrote on sidst redigeret af
                                        #162

                                        a bit strange when you look at the pipeline, poster on the right or https://virtualboothdemo.s3.amazonaws.com/Genmab/Content/PDFs/ash/I FINAL PIPELINE.pdf , it shows HexaBody CD38 in development phase I/II

                                        1 Reply Last reply
                                        0
                                        • BulderB Offline
                                          BulderB Offline
                                          Bulder
                                          wrote on sidst redigeret af
                                          #163

                                          Must be because they plan to start one "soon".

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger